Genmab A/S

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody - drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Current securities

1. 6-K filingSep 24, 2026
2. 6-K filingSep 9, 2026
3. 6-K filingSep 9, 2026
4. 6-K filingSep 8, 2026
5. 6-K filingAug 11, 2026